Premium
ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Author(s) -
Song Y.,
Zhou K.,
Zou D.,
Zhou J.,
Hu J.,
Yang H.,
Zhang H.,
Ji J.,
Xu W.,
Jin J.,
Lv F.,
Feng R.,
Gao S.,
Zhou D.,
Guo H.,
Wang A.,
Elstrom R.,
Huang J.,
Novotny W.,
Han L.,
Zhu J.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.15_2629
Subject(s) - medicine , mantle cell lymphoma , discontinuation , clinical endpoint , neutropenia , ibrutinib , progression free survival , phases of clinical research , adverse effect , refractory (planetary science) , gastroenterology , oncology , surgery , toxicity , lymphoma , chemotherapy , clinical trial , leukemia , chronic lymphocytic leukemia , physics , astrobiology